SG11202003212PA - Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies - Google Patents

Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies

Info

Publication number: SG11202003212PA
Authority: SG; Singapore
Prior art keywords: antibodies; combinations
Prior art date: 2017-10-10

Application number

SG11202003212PA

Inventor

Ling Xu

Edward Seung

Lan Wu

Ronnie Wei

Gary Nabel

Zhi-Yong Yang

Tarik Dabdoubi

Béatrice Cameron

Cendrine Lemoine

Catherine Prades

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-10

Filing date

2018-10-09

Publication date

2020-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63963620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202003212P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-09 Application filed by Sanofi Sa filed Critical Sanofi Sa

2020-05-28 Publication of SG11202003212PA publication Critical patent/SG11202003212PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11202003212PA 2017-10-10 2018-10-09 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies SG11202003212PA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201762570655P	2017-10-10	2017-10-10
US201762570660P	2017-10-11	2017-10-11
US201862676221P	2018-05-24	2018-05-24
EP18187186		2018-08-03
PCT/US2018/055084 WO2019074973A2 (en)	2017-10-10	2018-10-09	Anti-cd38 antibodies and methods of use

Publications (1)

Publication Number	Publication Date
SG11202003212PA true SG11202003212PA (en)	2020-05-28

Family

ID=63963620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202003212PA SG11202003212PA (en)	2017-10-10	2018-10-09	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies

Country Status (19)

Country	Link
US (3)	US11186649B2 (en)
EP (2)	EP3694882B1 (en)
JP (3)	JP7036909B2 (en)
KR (1)	KR20200061402A (en)
CN (4)	CN120058938A (en)
AR (1)	AR116718A1 (en)
AU (1)	AU2018348093A1 (en)
BR (1)	BR112020007002A2 (en)
CA (1)	CA3078800A1 (en)
ES (1)	ES2986579T3 (en)
IL (1)	IL273871A (en)
MA (1)	MA50359A (en)
MX (1)	MX2020004129A (en)
MY (1)	MY199781A (en)
PH (1)	PH12020550408A1 (en)
SG (1)	SG11202003212PA (en)
TW (4)	TW202342544A (en)
UY (1)	UY37928A (en)
WO (1)	WO2019074973A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
TWI622597B (en) *	2011-03-28	2018-05-01	賽諾菲公司	Dual variable region antibody binding protein with cross-binding domain orientation
CA3211863A1 (en)	2013-01-14	2014-07-17	Xencor, Inc.	Novel heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
PE20171103A1 (en)	2014-11-26	2017-08-07	Xencor Inc	HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
DK3223845T3 (en)	2014-11-26	2021-08-16	Xencor Inc	HETERODIMERING ANTIBODIES BINDING CD3 AND CD20
CN114230668B (en) *	2015-01-23	2025-07-11	赛诺菲	Anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies specifically binding to CD3 and/or CD123
EP3365366B1 (en)	2015-10-25	2021-07-14	Sanofi	Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
HUE063824T2 (en)	2016-04-13	2024-02-28	Sanofi Sa	Trispecific and/or trivalent binding proteins
CN109476732B (en)	2016-04-13	2024-03-22	赛诺菲	Trispecific and/or trivalent binding proteins
EP3475304B1 (en)	2016-06-28	2022-03-23	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
IL271194B2 (en)	2017-06-20	2024-10-01	Teneobio Inc	Anti-BCMA antibodies containing only heavy chains
BR112020007002A2 (en) *	2017-10-10	2020-11-17	Sanofi	anti-cd38 antibodies and methods of use
CN112272563A (en)	2017-11-08	2021-01-26	Xencor股份有限公司	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10982006B2 (en)	2018-04-04	2021-04-20	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
CA3098374A1 (en)	2018-04-25	2019-10-31	Prometheus Biosciences, Inc.	Optimized anti-tl1a antibodies
BR112021006558A2 (en)	2018-10-09	2021-07-13	Sanofi	anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection
US12180298B2 (en)	2019-04-05	2024-12-31	Teneobio, Inc.	Heavy chain antibodies binding to PSMA
US11613576B2 (en) *	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
EP3953388A1 (en) *	2019-04-09	2022-02-16	Sanofi	Trispecific binding proteins, methods, and uses thereof
US20220306762A1 (en) *	2019-07-03	2022-09-29	Crystal Bioscience Inc.	Anti-cd38 antibody and methods of use thereof
JP7504992B2 (en)	2019-10-24	2024-06-24	プロメテウスバイオサイエンシーズ，インク．	Humanized antibodies against TNF-like ligand 1A (TL1A) and uses thereof
BR112022007664A2 (en)	2019-10-25	2022-08-09	Sanofi Sa	METHODS TO ANALYZE THE INCORRECT PAIRING OF CHAINS IN MULTISPECIFIC BINDING PROTEINS
CN112876563B (en) *	2019-11-29	2022-08-16	康诺亚生物医药科技（成都）有限公司	Pharmaceutical composition, preparation method and application thereof
JP7625007B2 (en)	2020-04-29	2025-01-31	テネオバイオ，インコーポレイテッド	Multispecific heavy chain antibodies having modified heavy chain constant regions
WO2021222578A1 (en) *	2020-04-29	2021-11-04	Teneobio, Inc.	Multispecific heavy chain antibodies with modified heavy chain constant regions
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
MX2023001962A (en)	2020-08-19	2023-04-26	Xencor Inc	Anti-cd28 and/or anti-b7h3 compositions.
EP4214234A1 (en) *	2020-09-18	2023-07-26	Regeneron Pharmaceuticals, Inc.	Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
US12144827B2 (en)	2021-02-25	2024-11-19	Lyell Immunopharma, Inc.	ROR1 targeting chimeric antigen receptor
EP4305067A1 (en)	2021-03-09	2024-01-17	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (en)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Heterodimeric antibody that binds to CD3 and GPC3
WO2023284806A1 (en) *	2021-07-14	2023-01-19	江苏恒瑞医药股份有限公司	Antigen-binding molecule that specifically binds to cd38, bcma and cd3 and medical uses thereof
EP4380977A2 (en) *	2021-08-02	2024-06-12	Hangzhou Unogen Biotech, Ltd	Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
WO2023021477A1 (en) *	2021-08-20	2023-02-23	Novartis Ag	Methods of making chimeric antigen receptor–expressing cells
EP4540284A2 (en)	2022-06-17	2025-04-23	Apogee Therapeutics, Inc.	Antibodies that bind interleukin 13 and methods of use
CN119487071A (en) *	2022-06-24	2025-02-18	北京可瑞生物科技有限公司	T cell receptor-based bispecific polypeptide molecules and their uses
WO2024206439A2 (en) *	2023-03-28	2024-10-03	Nkarta, Inc.	Antibodies and chimeric antigen receptors specific for cd38
WO2025027003A1 (en)	2023-07-31	2025-02-06	Sanofi	Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338518C (en)	1987-09-23	1996-08-13	Joyce M. Zarling	Antibody heteroconjugates for the killing of hiv-infected cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
ES2532910T3 (en)	1998-04-02	2015-04-01	Genentech, Inc.	Antibody variants and fragments thereof
CN1294148C (en)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	Single-stranded cyctic trispecific antibody
EP2395016A3 (en) *	2003-05-30	2012-12-19	Merus B.V.	Design and use of paired variable regions of specific binding molecules
EP1641827A2 (en) *	2003-06-27	2006-04-05	Biogen Idec MA Inc.	Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US9200061B2 (en) *	2004-02-06	2015-12-01	Morpho Sys AG	Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
WO2005103083A2 (en)	2004-02-06	2005-11-03	Morphosys Ag	Anti-cd38 human antibodies and uses therefor
CN100376599C (en)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering
NZ586780A (en) *	2005-03-23	2012-02-24	Genmab As	Antibodies against CD38 for treatment of multiple myeloma
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
SG191639A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2480572B1 (en)	2009-09-25	2019-01-30	The United States of America, as represented by The Secretary, Department of Health and Human Services	Neutralizing antibodies to hiv-1 and their use
RS59769B1 (en)	2010-06-09	2020-02-28	Genmab As	Antibodies against human cd38
JOP20210044A1 (en)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-CD38 . antibody
TWI622597B (en)	2011-03-28	2018-05-01	賽諾菲公司	Dual variable region antibody binding protein with cross-binding domain orientation
WO2012154312A1 (en)	2011-05-09	2012-11-15	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Neutralizing antibodies to hiv-1 and their use
CA2836468C (en)	2011-05-17	2021-05-04	The Rockefeller University	Human immunodeficiency virus neutralizing antibodies and methods of use thereof
BR112014010823B1 (en)	2011-11-07	2021-02-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	antibodies that bind to gp41 and neutralize human immunodeficiency virus type 1 (hiv-1), its uses, nucleic acid molecule, expression vector, composition, kit, as well as methods for detecting hiv-1 infection and potential immunogen test
US9695230B2 (en)	2011-12-08	2017-07-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
SI2794658T1 (en) *	2011-12-19	2017-05-31	Synimmune Gmbh	Bispecific antibody molecule
WO2013163427A1 (en)	2012-04-25	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibodies to treat hiv-1 infection
US9951106B2 (en)	2012-12-04	2018-04-24	University Of Maryland, Baltimore	Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20140213772A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) *	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
WO2014116846A2 (en)	2013-01-23	2014-07-31	Abbvie, Inc.	Methods and compositions for modulating an immune response
BR112015023557A2 (en)	2013-03-15	2017-10-24	Abbvie Inc	specific dual binding proteins directed against tnfa
SG10201909806SA (en)	2013-11-04	2019-11-28	Glenmark Pharmaceuticals Sa	Production of t cell retargeting hetero-dimeric immunoglobulins
HRP20200164T1 (en)	2014-03-28	2020-05-01	Xencor, Inc.	BISPECIFIC ANTIBODIES BINDING TO CD38 AND CD3
BR112017004270B1 (en)	2014-09-04	2023-03-07	Stemcell Technologies Inc	METHOD OF ACTIVATION OF T CELLS OR NK CELLS
CA2971732A1 (en) *	2014-12-23	2016-06-30	Bristol-Myers Squibb Company	Antibodies to tigit
CN114230668B (en)	2015-01-23	2025-07-11	赛诺菲	Anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies specifically binding to CD3 and/or CD123
WO2016196740A1 (en)	2015-06-02	2016-12-08	The Rockefeller University	Tri-specific antibodies for hiv therapy
EP3365366B1 (en)	2015-10-25	2021-07-14	Sanofi	Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
CN105837688B (en) *	2015-11-20	2019-02-26	北京大学深圳研究生院	Single domain antibody and its encoding gene, immunotoxin and its encoding gene, preparation method, expression vector, application, and host cell
CN109476732B (en)	2016-04-13	2024-03-22	赛诺菲	Trispecific and/or trivalent binding proteins
WO2018120842A1 (en)	2016-12-30	2018-07-05	上海欣百诺生物科技有限公司	Bifunctional molecule and use thereof
WO2018151841A1 (en)	2017-02-17	2018-08-23	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
BR112020007002A2 (en)	2017-10-10	2020-11-17	Sanofi	anti-cd38 antibodies and methods of use
BR112021006558A2 (en)	2018-10-09	2021-07-13	Sanofi	anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof

2018
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/en unknown
- 2018-10-09 MY MYPI2020001741A patent/MY199781A/en unknown
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/en active Active
- 2018-10-09 CN CN202510116993.7A patent/CN120058938A/en active Pending
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/en active Active
- 2018-10-09 CN CN201880079045.9A patent/CN111788225B/en active Active
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/en active Pending
- 2018-10-09 ES ES18792827T patent/ES2986579T3/en active Active
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/en not_active Application Discontinuation
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/en active Pending
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/en active Pending
- 2018-10-09 CA CA3078800A patent/CA3078800A1/en active Pending
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/en unknown
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 MA MA050359A patent/MA50359A/en unknown
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en not_active Abandoned
- 2018-10-09 CN CN202510123093.5A patent/CN120058939A/en active Pending
- 2018-10-10 UY UY0001037928A patent/UY37928A/en not_active Application Discontinuation
- 2018-10-11 TW TW112124284A patent/TW202342544A/en unknown
- 2018-10-11 TW TW112139671A patent/TW202432580A/en unknown
- 2018-10-11 TW TW107135898A patent/TWI821202B/en active
- 2018-10-11 TW TW112139669A patent/TW202430563A/en unknown
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/en unknown
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/en active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
2023
- 2023-11-14 JP JP2023193393A patent/JP2024020377A/en active Pending

Also Published As

Publication number	Publication date
AU2018348093A1 (en)	2020-05-28
MA50359A (en)	2020-08-19
JP2020536543A (en)	2020-12-17
US11365261B2 (en)	2022-06-21
JP2024020377A (en)	2024-02-14
TW202432580A (en)	2024-08-16
US20220275102A1 (en)	2022-09-01
EP3694882B1 (en)	2024-06-19
ES2986579T3 (en)	2024-11-12
CN120058938A (en)	2025-05-30
AR116718A1 (en)	2021-06-09
IL273871A (en)	2020-05-31
PH12020550408A1 (en)	2021-04-12
US20220041746A1 (en)	2022-02-10
EP4249068A3 (en)	2023-11-22
CN120058939A (en)	2025-05-30
US20190106504A1 (en)	2019-04-11
KR20200061402A (en)	2020-06-02
MY199781A (en)	2023-11-23
TW202342544A (en)	2023-11-01
CA3078800A1 (en)	2019-04-18
CN117964758A (en)	2024-05-03
US11186649B2 (en)	2021-11-30
RU2020115450A (en)	2021-11-15
JP7036909B2 (en)	2022-03-15
EP4249068A2 (en)	2023-09-27
TW202430563A (en)	2024-08-01
JP2022071087A (en)	2022-05-13
JP7387780B2 (en)	2023-11-28
EP3694882A2 (en)	2020-08-19
WO2019074973A3 (en)	2019-06-13
WO2019074973A2 (en)	2019-04-18
TW201930338A (en)	2019-08-01
BR112020007002A2 (en)	2020-11-17
CN111788225A (en)	2020-10-16
UY37928A (en)	2019-05-31
MX2020004129A (en)	2020-08-20
CN111788225B (en)	2025-02-18
TWI821202B (en)	2023-11-11

Publication	Publication Date	Title
IL273871A (en)	2020-05-31	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
IL278846A (en)	2021-01-31	Anti-cd3 antibodies and uses thereof
IL258036A (en)	2018-05-31	Optimized anti-cd3 bispecific antibodies and uses thereof
IL278844A (en)	2021-01-31	Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
IL279974B2 (en)	2025-07-01	Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL283493A (en)	2021-07-29	Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-phf-tau antibodies and uses thereof
IL253569A0 (en)	2017-09-28	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
ZA201908072B (en)	2023-04-26	Igf-1r monoclonal antibodies and uses thereof
EP3527590A4 (en)	2020-05-27	Anti-egfr and anti-cd3 bispecific antibody and applications thereof
AU2016210068A1 (en)	2017-09-07	Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
IL271128A (en)	2020-01-30	Novel anti-cd3 antibodies
IL263273B1 (en)	2025-06-01	Anti-gitr antibodies and uses thereof
SG10201912366YA (en)	2020-02-27	Anti-cd3 antibody and molecules comprising the antibody
EP3661555C0 (en)	2025-04-16	Bispecific antibodies and uses thereof
IL274202A (en)	2020-06-30	Anti-glyco-muc1 antibodies and their uses
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof
HK40100622A (en)	2024-05-03	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
HK40025714A (en)	2020-12-24	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
HK40115176A (en)	2025-03-28	Bispecific antibodies and uses thereof
HK40027107A (en)	2021-01-15	Novel anti-cd3 antibodies
HK40033364B (en)	2025-02-21	Bispecific antibodies and uses thereof
HK1239720B (en)	2021-04-16	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123